Updates in the Treatment of Pediatric Pulmonary Arterial Hypertension

Pediatric pulmonary arterial hypertension (PAH) is a relentless and potentially fatal disease marked by elevated pulmonary vascular resistance and pulmonary pressure as a result of unchecked vascular remodeling, proliferation, and dysfunction. While pharmacological treatment algorithms for adult PAH are well-established and frequently updated, pediatric PAH treatment guidelines in the United States are generally based on limited clinical trials and expert opinion, leaving clinicians to extrapolate from adult data and expert consensus rather than pediatric-specific, evidence-based protocols. Endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin-pathway agents remain the therapeutic cornerstone, yet clinical practice is being reshaped by pivotal therapeutic developments. Recent advances highlight differences in monotherapy versus combination pharmacological regimens, alongside active trials investigating interventional/surgical procedures in the amelioration of long-term outcomes. This review seeks to consolidate contemporary data and clinical trial highlights to reflect a necessary shift toward precise, developmentally informed pharmacotherapy in children, underscoring the pressing need for an updated pharmacological guideline that incorporates pediatric-specific trials and harmonizes labeling and long-term safety surveillance in the treatment of pediatric PAH.